title: [Clinical features and prognosis of t (8; 21)/AML1-ETO-positive childhood acute myeloid leukemia].
abstract: OBJECTIVE To study the clinical and biological characteristics and prognosis of t(8;21)/AML1-ETO-positive childhood acute myeloid leukemia (AML).
  
  
  METHODS
  The clinical data of 55 children who were diagnosed as t (8; 21)/AML1-ETO-positive AML were retrospectively studied. Event-free survival (EFS), disease-free survival (DFS), and overall survival (OS) rates were estimated by the Kaplan-Meier method. Prognostic factors were evaluated by COX regression analysis software.
  
  
  RESULTS
  Of the 55 patients, 4 patients gave up treatment after the diagnosis was confirmed and 4 patients were lost to follow-up after the first chemotherapy course. The remaining 47 patients received a double-induction therapy. The total complete remission (CR) rate was 71% and 94% after the first and second chemotherapy course, respectively. The disease was relapsed in 10 patients (21%). The 5-year EFS, DFS and OS rates were (56.1 ± 7.9)%, (59.8 ± 8.1)%, and (72.0 ± 8.1)%, respectively. Multivariate analysis showed that age was an independent risk factor for the long-term prognosis. The older children had a greater risk of experiencing an accident or death (P<0.05). The 5-year OS rate in 27 patients with regular consolidation chemotherapy was significantly higher than 13 patients with irregular chemotherapy after CRz [(47.5 ± 17.1)% vs (38.9 ± 17.3)%; P<0.01].
  
  
  CONCLUSIONS
  Childhood t(8;21)/AML1-ETO-positive AML is a highly heterogeneous disease, with a high CR rate and a good long-term prognosis. Age is one of the important factors affecting the long-term therapeutic effect. Regular consolidation chemotherapy applied after CR usually is helpful.
authors.affiliation: Department of Pediatrics, People's Hospital, Peking University, Beijing 100044, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Wu
authors.forename: Le-Ping
authors.initials: LP
authors.lastname: Zhang
authors.forename: Ai-Dong
authors.initials: AD
authors.lastname: Lu
authors.forename: Bin
authors.initials: B
authors.lastname: Wang
authors.forename: Yi-Fei
authors.initials: YF
authors.lastname: Cheng
authors.forename: Gui-Lan
authors.initials: GL
authors.lastname: Liu
mesh_terms: D000293:Adolescent; D001856:Bone Marrow Examination; D002648:Child; D002675:Child, Preschool; D002891:Chromosomes, Human, Pair 21; D002898:Chromosomes, Human, Pair 8; D050676:Core Binding Factor Alpha 2 Subunit / Q000032:analysis*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000401:mortality*; D008297:Male; D015514:Oncogene Proteins, Fusion / Q000032:analysis*; D011379:Prognosis; D000075142:RUNX1 Translocation Partner 1 Protein; D014178:Translocation, Genetic
chemical_list: C107844:AML1-ETO fusion protein, human; D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; D000075142:RUNX1 Translocation Partner 1 Protein